利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

401 条记录 (耗时 0.025 秒)

    PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    3.
    发明公开
    PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 审中-公开
    吡唑衍生物，或药物可接受的盐

    公开(公告)号：EP3315492A1

    公开(公告)日：2018-05-02

    申请号：EP16814372.5

    申请日：2016-06-22

    申请人： Kissei Pharmaceutical Co., Ltd.

    发明人： HIRASAWA, Hideaki ,  TANADA, Fumiya ,  MUTAI, Yousuke ,  FUSHIMI, Nobuhiko ,  KOBAYASHI, Junichi ,  KIJIMA, Yoshiro

    IPC分类号： C07D231/12 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/427 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61P11/02

    摘要： [Problem]
    The present invention is to provide a novel pyrazole derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof.
    [Solution]
    The present invention provides a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, which has TRPM8 inhibitory effects:

    wherein ring A is C 6-10 aryl or the like; X is CR 4a or the like; R 1 and R 2 are a hydrogen atom or the like; R 3 is a hydrogen atom or the like; R 4 is a hydrogen atom or the like; ring B is C 6-10 aryl or the like; R 5 is a hydrogen atom or the like; R 6a is a hydrogen atom or the like; R 7a is a hydrogen atom or the like; R 7b is a hydrogen atom or the like; R 6b is a hydrogen atom or the like; R 8 is a hydrogen atom or the like; n is 0, 1 or 2. Therefore, the compound represented by the formula (I) of the present invention or a pharmaceutically acceptable salt thereof is useful as an agent for treating or preventing diseases or symptoms caused by hyperexcitability or disorder of afferent neurons.

    摘要翻译： 本发明提供新的吡唑衍生物或其药学上可接受的盐，含有其的药物组合物及其药物用途。 本发明提供具有TRPM8抑制效果的式（I）所示的化合物或其药学上可接受的盐，其中环A为C 6-10芳基等; X是CR4a等; R1和R2是氢原子等; R3是氢原子等; R4是氢原子等; 环B是C 6-10芳基等; R5是氢原子等; R6a是氢原子等; R7a是氢原子等; R7b是氢原子等; R6b是氢原子等; R8是氢原子等; n为0,1或2.因此，由本发明的式（I）表示的化合物或其药学上可接受的盐可用作用于治疗或预防由传入神经元的兴奋过度或病症引起的疾病或症状的药剂。

    FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL USE THEREOF
    9.
    发明公开
    FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL USE THEREOF 审中-公开
    秘密药剂师联合会在西班牙药剂师VERWENDUNG

    公开(公告)号：EP2749562A1

    公开(公告)日：2014-07-02

    申请号：EP12825645.0

    申请日：2012-08-23

    申请人： Kissei Pharmaceutical Co., Ltd.

    发明人： SHIMIZU, Kazuo ,  ONDA, Yusuke ,  IIZUKA, Masato

    IPC分类号： C07D491/048 ,  A61K31/407 ,  A61P13/12 ,  A61P19/06 ,  A61P43/00 ,  C07D495/04

    CPC分类号： C07D495/04 ,  C07D333/24 ,  C07D491/048

    摘要： The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like.
    The present invention relates to fused heterocyclic derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, or prodrugs thereof, or pharmaceutically acceptable salts thereof.
    In the formula (I), ring U represents C 6-10 aryl or the like; R 1 independently represents a hydrogen atom, a hydroxy group, C 1-6 alkyl or the like; m represents an integral number from 1 to 2; ring Q represents 5-membered heteroaryl; n represents an integral number from 1 to 3; R 2 independently represents a hydrogen atom, a halogen atom, C 1-6 alkyl or the like.

    摘要翻译： 本发明提供可用作预防或治疗与血清尿酸水平异常等有关的疾病的药剂的化合物。 本发明涉及具有黄嘌呤氧化酶抑制活性的由下式（I）表示的稠合杂环衍生物，可用作预防或治疗与血清尿酸水平异常有关的疾病或其前药或药学上可接受的盐 它们。 在式（I）中，环U表示C 6-10芳基等; R 1独立地表示氢原子，羟基，C 1-6烷基等; m表示1〜2的整数; 环Q表示5元杂芳基; n表示1〜3的整数; R 2独立地表示氢原子，卤素原子，C 1-6烷基等。